解读免疫检查点抑制剂的影像学疾病稳定
本综述结合系统评价、癌症基因组图谱基因表达数据及非小细胞肺癌发现队列与外部验证队列,分析免疫检查点抑制剂治疗中按RECIST定义的疾病稳定(SD)。发现SD在不同瘤种占16%–42%,与肿瘤增殖指数相关而非ICI相对反应;非小细胞肺癌中PFS>6个月且无肿瘤生长的SD亚组生存与部分缓解相似,被提出为SD应答者定义。
要点
- 免疫检查点抑制剂试验中SD占16%–42%,在不同瘤种间异质性大。
- 非小细胞肺癌SD患者PFS范围0.2–49个月,中位4.9个月。
- PFS>6个月且无肿瘤生长的SD亚组总生存风险比1.0,被提出为SD应答者定义。
核心结论
- RECIST定义的免疫治疗SD常见、异质,可能主要反映肿瘤生长速率而非ICI反应。
- 非小细胞肺癌SD患者中PFS>6个月且无肿瘤生长者可考虑为「SD应答者」,该定义可能提高临床与转化研究效率。
研究设计与样本
- 系统评价纳入59项ICI研究、14280例患者以描述SD。
- 利用癌症基因组图谱基因表达数据比较SD与客观缓解同增殖指数的关系。
- 非小细胞肺癌发现队列1220例,其中313例(26%)为ICI治疗SD,测试%最佳总体反应与PFS连续切点定义SD应答者。
- 结果在来自durvalumab治疗非小细胞肺癌试验的两个验证队列中检验。
主要发现
- 不同瘤种SD范围为16%–42%,与疾病特异性增殖指数相关(ρ=-0.75,P=0.03),而非ICI相对反应。
- 非小细胞肺癌SD患者PFS范围0.2–49个月,中位4.9个月。
- PFS>6个月且无肿瘤生长的SD亚组与部分缓解轻微(PR minor)相似,总生存风险比1.0。
- 该定义在两个durvalumab治疗非小细胞肺癌验证队列中得到确认,并适用于深度与持续时间获益相关的免疫治疗瘤种。
关键数值与推荐
- SD应答者定义:PFS>6个月且无肿瘤生长。
- SD与增殖指数相关ρ=-0.75,P=0.03。
- SD应答者总生存风险比1.0(与部分缓解轻微相似)。
临床怎么用
- 作者认为,非小细胞肺癌ICI治疗后SD且PFS>6个月、无肿瘤生长者可考虑为「SD应答者」。
- 作者认为该定义可能提高临床与转化研究效率及可推导的洞见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 'Stable disease (SD)' as per RECIST is a common but ambiguous outcome in patients receiving immune checkpoint inhibitors (ICIs). This study aimed to characterize SD and identify the subset of patients with SD who are benefiting from treatment. Understanding SD would facilitate drug development and improve precision in correlative research. PATIENTS AND METHODS: A systematic review was carried out to characterize SD in ICI trials. SD and objective response were compared to proliferation index using The Cancer Genome Atlas gene expression data. To identify a subgroup of SD with outcomes mirroring responders, we examined a discovery cohort of non-small-cell lung cancer (NSCLC). Serial cutpoints of two variables, % best overall response and progression-free survival (PFS), were tested to define a subgroup of patients with SD with similar survival as responders. Results were then tested in external validation cohorts. RESULTS: Among trials of ICIs (59 studies, 14 280 patients), SD ranged from 16% to 42% in different tumor types and was associated with disease-specific proliferation index (ρ = -0.75, P = 0.03), a proxy of tumor kinetics, rather than relative response to ICIs. In a discovery cohort of NSCLC [1220 patients, 313 (26%) with SD to ICIs], PFS ranged widely in SD (0.2-49 months, median 4.9 months). The subset with PFS >6 months and no tumor growth mirrored partial response (PR) minor (overall survival hazard ratio 1.0) and was proposed as the definition of SD responder. This definition was confirmed in two validation cohorts from trials of NSCLC treated with durvalumab and found to apply in tumor types treated with immunotherapy in which depth and duration of benefit were correlated. CONCLUSIONS: RECIST-defined SD to immunotherapy is common, heterogeneous, and may largely reflect tumor growth rate rather than ICI response. In patients with NSCLC and SD to ICIs, PFS >6 months and no tumor growth may be considered 'SD responders'. This definition may improve the efficiency of and insight derivable from clinical and translational research.
引用
- Luo J, Wu S, Rizvi H, et al. Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol. 2022. PMID: 35533926. doi:10.1016/j.annonc.2022.04.450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。